Article

Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells

2022-04-08

Abstract excerpt

<h4>ABSTRACT</h4> Acute myeloid leukemias (AML) are comprised of multiple cell types with distinct capabilities to propagate the disease and resist therapy. Approximately 20% of AML patients carry gain- of-function mutations in IDH1 or IDH2 that result in over-production of the onco-metabolite 2-HG. Although IDH inhibitors can induce complete morphological remission, almost all patients eventually relapse. Analys...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fc84c069-4018-5a7d-912c-dae16ee1a670
DOI: 10.1101/2022.04.06.487420

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cellsDOI 10.1101/2022.04.06.487420Read

Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells.Semantic proximity Read

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.Semantic proximity Read

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.Semantic proximity Read

AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in VivoSemantic proximity Read

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.Semantic proximity Read

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.Semantic proximity Read

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex VivoSemantic proximity Read

Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.Semantic proximity Read

Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation.Semantic proximity Read

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersSemantic proximity Read

Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.Semantic proximity Read

The Leukemic IDH1/2 Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPC): Experimental Evidences and a Review of the LiteratureSemantic proximity Read